Targeting DNA Mismatch Repair as a Potential Therapeutic Strategy for Huntington’s Disease

July 1st, 2025|Categories: Perspectives on Current Science|

Huntington's disease (HD) is a devastating and fatal neurodegenerative disorder affecting movement, thinking, and behavior. In the United States alone, there are approximately 40,000 people with symptomatic Huntington's disease, and more than 200,000 are at risk of inheriting it. The fatal disease often leaves ...

NanoCas: A Newly Identified Compact Nuclease May Expand CRISPR’s Reach

June 3rd, 2025|Categories: Perspectives on Current Science|

The revolutionary CRISPR-Cas system has proven to be a precise method for genome editing, showing great promise in tackling genetic disorders. However, clinical trials for CRISPR-based treatments have faced delivery challenges due to the large size of the editing system. In the quest to ...

OTS Member Highlight – Holly Kordasiewicz, PhD

May 13th, 2025|Categories: Perspectives on Current Science|

Holly Kordasiewicz was a curious, chatty child with a penchant for asking questions. At dinner, conversations were often about the fascinating things her mom, a registered nurse, learned at work, sparking Kordasiewicz's interest in medicine and biology. As her grandparents aged, and she witnessed ...

2024 FDA Approvals: A Wave of Innovation in Treating Serious Diseases

February 25th, 2025|Categories: Perspectives on Current Science|

In 2024, the Food and Drug Administration Center for Drug Evaluation (CDER) approved 50 new small molecules, biologics, and oligonucleotide therapies (1). The approvals — the second largest in 30 years — include an oligonucleotide therapy for blood cancer, an antisense oligonucleotide shown to ...

Transporting Therapeutics: A Novel Approach to Deliver ASOs to the Brain

February 12th, 2025|Categories: Perspectives on Current Science|

Antisense oligonucleotide (ASO) therapies, which bind to RNA and modify protein expression, are promising drugs for treating neurological conditions. However, their inability to cross the blood-brain barrier (BBB) sometimes makes injection directly into the cerebral spinal fluid (via intrathecal injection) necessary, which is not ...

Oligonucleotide Treatment Advances Offer Relief for Patients with Familial Chylomicronemia Syndrome

February 5th, 2025|Categories: Perspectives on Current Science|

At just three weeks old, Darlene was sent to the emergency room after her mom had brought her to a pediatrician. The baby wouldn't stop crying and wasn't eating. Concerningly, her triglyceride levels were in the 20,000's, far over the normal 150 level. Darlene ...

Go to Top